Themis Medicare (BOM:530199) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530199 Themis Medicare Ltd BOM:530199
69 GF Score
Price ₹120.40
GF Value ₹141.75
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Themis Medicare Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Themis Medicare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Themis Medicare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Themis Medicare's annualized EBITDA for the quarter that ended in Jun. 2026 was ₹1,661 Mil. Themis Medicare's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Themis Medicare's Debt-to-EBITDA or its related term are showing as below:

BOM:530199' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.72   Med: 1.64   Max: 14.1
Current: 1.32

During the past 13 years, the highest Debt-to-EBITDA Ratio of Themis Medicare was 14.10. The lowest was 0.72. And the median was 1.64.

BOM:530199's Debt-to-EBITDA is ranked better than
55.31% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs BOM:530199: 1.32

Themis Medicare  (BOM:530199) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Themis Medicare Debt-to-EBITDA Related Terms


Themis Medicare Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Themis Medicare's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Themis Medicare Debt-to-EBITDA Chart

Themis Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 1.17 1.70 1.55 11.26

Themis Medicare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A -27.79 N/A 11.26 N/A

BOM:530199 vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Themis Medicare Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Themis Medicare's Debt-to-EBITDA falls into.


BOM:530199
69GF Score
Themis Medicare Ltd BOM:530199
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Themis Medicare Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Themis Medicare's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(782.289 + 197.366) / 88.895
=11.02

Themis Medicare's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + 0) / 1661.064
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Themis Medicare (BOM:530199) Overvalued in 2026?

Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued. The current stock price of ₹120.40 is trading 15.1% below its estimated GF Value™ of ₹141.75. GuruFocus considers Themis Medicare to be Modestly Undervalued.

Key valuation signals for BOM:530199:

  • Debt-to-EBITDA: N/A
  • GF Value™: ₹141.75 vs. price of ₹120.40 (15.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the BOM:530199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Themis Medicare Business Description

Other Exchanges THEMISMED:India
Address Swami Vivekanand Road, 11/12, Udyog Nagar Industrial Estate, Goregaon (West), Mumbai, MH, IND, 400 104
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
69GF Score

Get the complete analysis for BOM:530199

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹120.40
Price
₹141.75
GF Value